Objective To explore the effects of sacral neuromodulation (SNM) on urodynamic parameters during the storage phase in patients with neurogenic bladder (NB), so as to provide reference for evaluating the efficacy of SNM. Methods A total 49 NB patients undergoing SNM at our hospital during Oct.2012 and May 2025 were enrolled. Baseline data and video-urodynamic parameters were collected. Changes in maximum cystometric capacity, maximum detrusor pressure during storage phase, and bladder compliance before and after treatment were assessed. Improvements in detrusor overactivity (DO) and vesicoureteral reflux (VUR) were also analyzed. Results Among the 49 patients,27 were male and 22 were female, with a mean age of (37.41±15.15) years, a median disease duration of 5.0 (2.0,15.5) years, and a median follow-up of 11 (1,32) months. Up to 37 patients (75.5%) received permanent sacral nerve pulse generator implantation (permanent implant group), while the remaining 12 were classified as the non-permanent implant group. Before and after the test period, all patients showed a significant increase in maximum cystometric capacity [ (218.0 (93.0,358.5) mL vs.300.0 (238.5, 400.0) mL, P<0.001], a decrease in maximum detrusor pressure during the filling phase [32.0 (13.5,71.0) cmH_2 O vs. 20.0 (9.0,50.0) cmH_2 O, P<0.001], and an improvement in bladder compliance [11.8 (8.3,25.6) mL/cmH_2 O vs.26.7 (8.6,44.1) mL/cmH_2O, P<0.001]. In the permanent implant group, comparisons before and after the test period showed an increase in maximum bladder capacity [ (239.16±147.23) mL vs. (312.24±121.83) mL, P<0.001], a decrease in maximum detrusor pressure during filling[32.0 (15.0,58.0) cmH_2 O vs.15.0 (9.0,41.0) cmH_2 O, P<0.05], and improved bladder compliance [10.8 (8.3,23.6) mL/cmH_2 O vs.28.6 (8.6,41.4) mL/cmH_2 O, P<0.001]. No statistically significant differences in these parameters before and after the test period were observed in the non-permanent implant group (P>0.05). A total of 17 patients in the permanent implant group underwent follow-up video urodynamics. Compared to pre-test values, significant improvements were observed in maximum detrusor pressure during filling, and bladder compliance both at the end of the test period and at the last follow-up (P<0.05). However, no statistically significant differences were found in maximum cystometric capacity, maximum detrusor pressure during filling, and bladder compliance between the end of the test period and the last follow-up (P>0.05). Among the 49 patients,21 had DO and 20 had VUR. Both DO and VUR showed improvement after the test period and at the last follow-up. Conclusion SNM can effectively improve storage function in NB patients, ameliorate detrusor overactivity and bladder compliance, and relieve or eliminate VUR in some patients. Long-term follow-up confirms that SNM provides stable therapeutic effects, demonstrating significant clinical value.

Objective:To study the effect of recombinant human growth hormone on height and serum insulin-like growth factor 1(IGF-1) in children with idiopathic short stature.Methods:Fifty children with idiopathic short stature admitted to Weihai Central Hospital from September 2015 to February 2017 were randomly divided into treatment group(25 cases) and control group(25 cases) according to the random digital table method.The control group received nutritional support treatment.The treatment group was treated with subcutaneous injection of recombinant human growth hormone on the basis of the control group.All the children were treated and observed for one year.The height, weight, growth rate, bone age, total thyroid hormone level, fasting blood glucose level, serum IGF-1 level and adverse reactions were compared before and after treatment.Results:After 1 year of treatment, the height, growth rate, and IGF-1 of the two groups were significantly higher than those before treatment ( t=4.427, 2.987, 7.459, 5.963, 31.389, 21.790, P<0.001, 0.004, <0.001, <0.001, <0.001, <0.001). which in the treatment group were significantly higher than those in the control group ( t=2.914, 2.480, 12.090, P=0.006, 0.017, <0.001). The body weight, bone age, total thyroid hormone levels, and fasting blood glucose levels in the two groups were not significantly different from those before treatment ( t=0.548, 1.931, 0.300, 1.367, 0.735, 0.759, 0.693, 0.920, P=0.586, 0.060, 0.765, 0.179, 0.466, 0.452, 0.492, 0.362), and there were no statistically significant differences between the two groups ( t=0.371, 0.141, 0.059, 0.318, P=0.713, 0.889, 0.953, 0.752). There was no statistically significant difference in adverse reactions between the two groups during treatment (χ 2=2.083, P=0.149). Conclusion:Recombinant human growth factor can effectively accelerate the growth rate of children with idiopathic short stature, increase the height of children, increase the level of serum IGF-1, and has no obvious side effects.